Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Marino-Ocampo, Nory ; Rodriguez, Diego F. ; Guerra Diaz, Daniel , et al. Int. J. Mol. Sci.,2023,24(5):4900. DOI: 10.3390/ijms24054900 PubMed ID: 36902328
More
Abstract: Direct FXa inhibitors are an important class of bioactive mols. (rivaroxaban, apixaban, edoxaban, and betrixaban) applied for thromboprophylaxis in diverse cardiovascular pathologies. The interaction of active compounds with human serum albumin (HSA), the most abundant protein in blood plasma, is a key research area and provides crucial information about drugs' pharmacokinetics and pharmacodynamic properties. This research focuses on the study of the interactions between HSA and four com. available direct oral FXa inhibitors, applying methodologies including steady-state and time-resolved fluorescence, isothermal titration calorimetry (ITC), and mol. dynamics. The HSA complexation of FXa inhibitors was found to occur via static quenching, and the complex formation in the ground states affects the fluorescence of HSA, with a moderate binding constant of 104 M-1. However, the ITC studies reported significantly different binding constants (103 M-1) compared with the results obtained through spectrophotometric methods. The suspected binding mode is supported by mol. dynamics simulations, where the predominant interactions were hydrogen bonds and hydrophobic interactions (mainly π-π stacking interactions between the Ph ring of FXa inhibitors and the indole moiety of Trp214). Finally, the possible implications of the obtained results regarding pathologies such as hypoalbuminemia are briefly discussed.
Keywords: FXa inhibitors ; human serum albumin ; fluorescence ; isothermal titration calorimetry ; molecular modeling ; direct oral FXa inhibitors ; commercially available FXa inhibitors ; apixaban ; rivaroxaban ; edoxaban ; betrixaban ...More
Purchased from AmBeed: 503612-47-3 ; 366789-02-8 ; 330942-05-7
CAS No. : | 503612-47-3 | MDL No. : | MFCD11977295 |
Formula : | C25H25N5O4 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | QNZCBYKSOIHPEH-UHFFFAOYSA-N |
M.W : | 459.50 | Pubchem ID : | 10182969 |
Synonyms : |
BMS-562247-01
|
Chemical Name : | 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide |
Signal Word: | Danger | Class: | N/A |
Precautionary Statements: | P260-P264-P270-P314-P501 | UN#: | N/A |
Hazard Statements: | H372 | Packing Group: | N/A |
GHS Pictogram: |